229
0 Kommentare
Philip Morris International Releases 2021 Integrated Report, Introducing New Sustainability Strategy and Sustainability Index - Seite 3
information on our ESG risks and performance, including data related to our company’s transformation, offering our stakeholders visibility into the future we are working toward,” said Jennifer Motles, Chief Sustainability Officer at PMI. “2021 was a year full of achievements, but challenges remain. As we continue to transform, learn, and discover better ways to develop solutions that have meaningful impact, we hope our transparency and willingness to engage will spark dialogue with those who can help accelerate the pace of change.”
The preparation of the 2021 Integrated Report considers guidance of international standards and frameworks, including: the Global Reporting Initiative (GRI); the UN Global Compact (UNGC); the UN Sustainable Development Goals; the Value Reporting Foundation (VRF), including use of its SASB Standards, Integrated Thinking Principles, and Integrated Reporting Framework; and some of the recommendations from the Task Force on Climate-related Financial Disclosures (TCFD).
To read the report, visit PMI Integrated Report 2021; to find out more about sustainability at PMI, please click here to visit the website.
Lesen Sie auch
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and
evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free
products, including heat not-burn, vapor, and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically
substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the
building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food
and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as Modified Risk Tobacco Products (MRTPs), finding that exposure
modification orders for these products are appropriate to promote the public health. As of March 31, 2022, PMI’s smoke-free products were available for sale in 71 markets. With a strong foundation
and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to
address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.